NEW YORK, January 11, 2017 /PRNewswire/ --
http://www.Financialbuzz.com - The future of the legal cannabis
market depends on a variety of factors. Politically, some have expressed concerns regarding the incoming elected administration,
others feel more optimistic after nine states have voted this election cycle. The results overwhelmingly came in favor of
legalization of cannabis for medical and recreational use. Economically, the industry has shown tremendous growth year to year.
According to a research published on January 3rd 2017 by ArcView Group, the legal cannabis sales in
the U.S. last year reached $6.7 billion, a growth of 30 percent from 2015. Sales are projected to
increase to $20.2 billion by the year 2021 representing a 25 percent compound annual growth rate.
MassRoots, Inc. (OTC: MSRT), Cara Therapeutics Inc. (NASDAQ: CARA), Insys Therapeutics Inc. (NASDAQ: INSY), GW Pharmaceuticals
(NASDAQ: GWPH), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE)
In an interview to Forbes, Arcview's editor-in-chief Tom Adams said that, "the only consumer
industry categories I've seen reach $5 billion in annual spending and then post anything like 25%
compound annual growth in the next five years are cable television (19%) in the 1990's and the broadband internet (29%) in the
2000's." ArcView Chief Executive Officer Troy Dayton added, "One of the biggest stories was the
alternative forms of ingestion… Concentrates and edibles are becoming customer favorites versus traditional smoking."
MassRoots, Inc. (OTCQB: MSRT) offers technology platforms for the cannabis industry. The Company's mobile applications
enable consumers to provide community-driven reviews of cannabis strains and products, enabling consumers to make cannabis
purchasing decisions. Yesterday the company announced that the company has launched an update to iOS mobile
application, available through the Apple App Store.
In a press release MassRoots described the new features, "Geo-targeted native advertisements in MassRoots' local, buds and
global feeds, enabling businesses to target advertisements to cannabis consumers in their local area. In depth strain and product
pages with high quality photos and descriptions, enabling users to learn about their favorite strains and products and see what
fellow enthusiasts have to say about them. Revamped reporting and content screening mechanisms, in addition to an enhanced
geo-fence, to ensure MassRoots remains in compliance with state cannabis regulations and the Cole Memorandum."
MassRoots CEO Isaac Dietrich said in a statement, "Management believes that this update offers
cannabis consumers the easiest way to find the best products at their local dispensary… The Company prides itself on our ability
to leverage new technology in order to better serve the regulated cannabis industry. We look forward to continuing to
introduce new features to our mobile applications to increase user engagement and drive revenue growth."
Clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate
pain and pruritus by selectively targeting kappa opioid receptors, Cara Therapeutics Inc. (NASDAQ: CARA), has recently
announced that it has completed patient enrollment for the multi-dose phase of its adaptive Phase 2/3 trial of I.V. CR845 in
dialysis patients suffering from moderate-to-severe uremic pruritus. "We're very pleased to have completed enrollment as planned
for Part A of the Phase 2/3 trial in pruritus associated with chronic kidney disease, as these eight-week data will determine the
optimal dosing to carry forward into planned registration trials. In our previous Phase 2 trial, I.V. CR845 significantly reduced
itch and improved the quality of life for dialysis patients with this condition over a two-week treatment period," said
Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. "We look
forward to reporting top-line data from Part A of this trial in the first quarter of 2017 and, based on the results, initiating
the planned registration phase later in the year."
Insys Therapeutics Inc. (NASDAQ: INSY) is a commercial-stage specialty pharmaceutical company. The Company develops and
commercializes supportive care products. The company markets Subsys, a sublingual fentanyl spray for breakthrough cancer pain in
opioid-tolerant cancer patients in the US. Its lead product candidate is Syndros, an orally administered liquid formulation of
dronabinol. The company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy
syndromes; and other product candidates, including other dronabinol line extensions and sublingual spray product candidates.
GW Pharmaceuticals (NASDAQ: GWPH) is involved in the development of cannabinoid prescription medicines using botanical
extracts derived from the Cannabis Sativa plant. Epidiolex is GW's lead cannabinoid product candidate and is a proprietary oral
solution of pure plant-derived cannabidiol, or CBD. GW's Epidiolex development is initially concentrating on severe, orphan,
early-onset, treatment-resistant epilepsy syndromes including Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis
Complex and Infantile Spasms. The company's current Phase 3 pivotal trials program for Epidiolex includes two Phase 3 trials in
Dravet syndrome, two in LGS, one in TSC, and one in IS. The first two of these Phase 3 trials, one in Dravet syndrome and one in
LGS, have showed significantly greater reductions in specific seizure types for patients taking Epidiolex compared to those
taking placebo.
Clinical-stage pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments
for patients with high unmet medical needs, Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) is currently in development of two
proprietary products: a transdermal synthetic cannabidiol gel for refractory epilepsy, osteoarthritis and Fragile X syndrome and
a novel synthetic THC pro-drug transdermal patch for two pain indications fibromyalgia and peripheral neuropathic pain.
Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts
on Trending Financial News from all these companies. "The Latest Buzz in Financial News"
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
About FinancialBuzz.com
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News,
Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company
Interviews. A pioneer in the financially driven digital space, video production and integration of social media,
FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and
advertising for third parties for disseminating news and original content through our unique media platform that includes
Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not
undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com the "Site") is either original financial news or paid advertisements provided
[exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and PR marketing firm enters into
service agreements with the companies which are the subject to the articles posted on the Site for advertising such companies.
Financialbuzz.com has been compensated tweleve thousand dollars for financial news dissemination and PR services by a third party
non affiliate for massroots inc. We are not an independent news media provider and therefore do not represent or warrant that the
information posted on the site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting
high quality and sophisticated content on this site along with other financial news PR media services. Our fees may be either a
flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities
are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion
of the engagement. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post
information about any companies the information contained herein is not intended to be used as the basis for investment decisions
and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or
solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or
losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations
that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions
based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition.
FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy,
as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any
investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is
suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining
whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial
situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any
investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All
materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy
and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com
For further information:
Media Contact: info@financialbuzz.com , +1-877-601-1879
SOURCE FinancialBuzz.com